Adaptimmune (ADAP) and TCR2 (TCRR) to Merge
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
March 6, 2023 6:01 AM ESTCompelling clinical data with clear paths to products and multiple nearterm value-creating catalysts
Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies
Following closing of the transaction, cash runway extended into 2026
Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR Therapeutics stockholders will own ~25% of the combined company
